AXSOME THERAPEUTICS INC secured United States FDA approval for its drug to treat Alzheimer's-related agitation on April 30. This decision opens a market serving a high-unmet-need population, positioning the developer to capture revenue from a condition affecting millions.

Expanding the Alzheimer's Treatment Landscape